Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

NCT02888379 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: TOP1288
DRUG: Placebo (for TOP1288)

Sponsor

Topivert Pharma Ltd